Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
  • A61P35/04—Antineoplastic agents specific for metastasis
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
  • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
  • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
  • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents

Definitions

• a combination of everolimus and amcenestrant a pharmaceutical composition containing such combination, and the therapeutic uses of such combination and pharmaceutical composition, in particular for the treatment of cancer.
• the estrogen receptor a (ESR1 ) is expressed in the majority of breast tumors, enabling them to respond to the mitogenic actions of estrogens.
• Everolimus is an inhibitor of mammalian target of rapamycin (mTOR). It has the following formula:
• Everolimus is a marketed drug, with AFINITOR ® as one of its tradenames. It is indicated in several oncology settings. In breast cancer, everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer in combination with exemestane after failure of treatment with letrozole or anastrozole (FDA label). There is always a need to find new antitumoral treatments. Now, it is shown herein that a combination of amcenestrant with everolimus demonstrates significant anti-tumor efficacy, and induces tumor regression, with a synergistic effect compared to each of the active ingredient alone.
• HR advanced hormone receptor
• HER2 human epidermal growth factor receptor 2
• amcenestrant may exist not only in the form of a zwitterion (i.e., a globally neutral molecule having an acid group and a basic group), but also in the form of addition salts with acids or bases. Such addition salts may be used in the above combination.
• a combination comprising amcenestrant, or a pharmaceutically acceptable salt thereof, and everolimus.
• amcenestrant or a pharmaceutically acceptable salt thereof, and everolimus for its use as a medicament.
• composition comprising amcenestrant, or a pharmaceutically acceptable salt thereof, and everolimus, as well as at least one pharmaceutically acceptable excipient.
• excipients are selected from the customary excipients which are known to a person skilled in the art. More particularly, the excipients are selected from those useful for oral administration in whatever form (liquid solution, dispersion or suspension, tablets, capsules, or the like).
• amcenestrant, or a pharmaceutically acceptable salt thereof, and everolimus may be administered simultaneously, separately, or spaced out over a period of time (sequential administration). Therefore, the combination and pharmaceutical composition provided herein are not exclusively limited to the ones which are obtained by physical association of the constituents in a single unit dosage, but also to those which allow a separate administration, which can be simultaneous or sequential (also called “spaced out” or “spread out”) over a period of time.
• a pharmaceutical kit which comprises:
• a second pharmaceutical composition comprising everolimus, and at least one pharmaceutically acceptable excipient; wherein the first pharmaceutical composition and the second pharmaceutical composition are in separate compartments and are intended to be independently administered, each administration with regards to the other one being simultaneous or spaced out (sequential) over time.
• amcenestrant or a pharmaceutically acceptable salt thereof, and everolimus, as well as a pharmaceutical composition and kit as described above, for use in the treatment of cancer.
• amcenestrant or a pharmaceutically acceptable salt thereof for use in the treatment of cancer by co-administration with everolimus.
• everolimus for use in the treatment of cancer by co administration with amcenestrant or a pharmaceutically acceptable salt thereof.
• Co-administration is understood herein as an administration of the active ingredients to a patient in need thereof, which is separated, simultaneous or spaced out (sequential) over time, with respect to each of the active ingredients.
• amcenestrant, or a pharmaceutically acceptable salt thereof, and everolimus are administered in a therapeutically effective amount.
• a “therapeutically effective amount” means the amount of an active ingredient or combination of active ingredients that, when administered to a patient for treating a disease, is sufficient to affect such treatment for the disease.
• the “therapeutically effective amount” will vary depending on the disease and its severity and the age, weight, etc., of the subject to be treated.
• amcenestrant, or a pharmaceutically acceptable salt thereof, and everolimus are administered in an amount to show therapeutic synergy.
• the cancer is a hormone dependent cancer.
• the cancer is an estrogen receptor dependent cancer, particularly the cancer is an estrogen receptor a dependent cancer.
• a method of treating the pathological conditions indicated above, particularly breast cancer comprising administering to a subject in need thereof a pharmaceutical composition or a pharmaceutical kit as described above.
• a method of treating the pathological conditions indicated above, particularly breast cancer comprising administering to a subject in need thereof a combination as described above.
• a method of treating the pathological conditions indicated above, particularly breast cancer comprising co-administering to a subject in need thereof amcenestrant or a pharmaceutically acceptable salt thereof and everolimus.
• amcenestrant, or a pharmaceutically acceptable salt thereof is administered with everolimus either separately, simultaneously or spaced out over time.
• a method of treating the pathological conditions indicated above, particularly breast cancer comprising co-administering to a subject in need thereof everolimus and amcenestrant, or a pharmaceutically acceptable salt thereof.
• everolimus is administered with amcenestrant, or a pharmaceutically acceptable salt thereof, either separately, simultaneously or spaced out over time.
• a method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of amcenestrant or a pharmaceutically acceptable salt thereof in combination with a therapeutically effective amount of everolimus.
• a method of treating cancer in a patient who is on therapy with compound amcenestrant, or a pharmaceutically acceptable salt thereof comprising administering to said patient an effective amount of everolimus.
• a method of treating cancer in a patient on stable treatment with compound amcenestrant, or a pharmaceutically acceptable salt thereof comprising administering to said patient a therapeutically effective amount of everolimus.
• a method of treating cancer comprising administering to a patient in need thereof a therapeutically effective amount of compound everolimus, wherein said patient is also on therapy with amcenestrant or a pharmaceutically acceptable salt thereof.
• the subject is a mammal. In another embodiment, the subject is a human.
• amcenestrant or a pharmaceutically acceptable salt thereof, and everolimus for the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer.
• amcenestrant or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer, by co-administration with everolimus.
• everolimus in the manufacture of a medicament useful in treating the pathological conditions indicated above, particularly breast cancer, by co-administration with amcenestrant or a pharmaceutically acceptable salt thereof.
• an article of manufacture comprising:
• the treated groups included amcenestrant at 10 mg/kg alone, everolimus at 10 mg/kg alone, and the combination of amcenestrant and everolimus at the same dose and regime.
• amcenestrant was orally dosed twice a day (BID)
• everolimus was orally dosed twice a week (BIW).
• Anti-tumor efficacy was evaluated by tumor volume measurement.
• mice Female NOD/SCID mice were obtained from GemPharmatech Co., Ltd (Nanjing University National Resource Center for Mutant Mice, Model Animal Research Center) (Nanjing, CHINA). Animals were allowed to acclimate for at least four days before the study enrollment. Mice were 7 to 8 weeks old and weighed between 22.5 and 28.4 grams at the beginning of the treatments. These animals were housed under conditions outlined in the guidelines approved by the Institutional Animal Care and Use Committee (IACUC) of CrownBio following the guidance of the Association for Assessment and Accreditation of Laboratory Animal Care (AAALAC).
• IACUC Institutional Animal Care and Use Committee
• MCF7 cells were obtained from the American Type Culture Collection (ATCC® HTB-22TM).
• the MCF7 tumor cells were maintained in vitro with MEM medium supplemented with 10% fetal bovine serum, 0.01 mM non-essential amino acid, 0.01 mg/ml bovine insulin, and 2 mM L-glutamine at 37°C in an atmosphere of 5% C02 in air.
• the cells in exponential growth phase were harvested and quantitated by cell counter before tumor inoculation.
• mice The mouse was subcutaneously implanted with estrogen pellets (0.18 mg/pellet, 17b- estradiol, Alternative Research of America, Sarasota, Florida, USA), hereafter referred to as ⁇ 2 supplement”, at the right flank one day before the tumor inoculation.
• ⁇ 2 supplement a supplement to which estrogen pellets were administered.
• MCF-7 tumor cells (2 x 10e7) in 0.25 ml of PBS/Matrigel (1 :1) mixture at the right mammary fat pad for tumor development.
• Everolimus (Manufacturer: Selleck; Lot number: S1120) was formulated in 30% propylene glycol (dissolve first): 5% Tween 80: 65% ddFi 2 0 (double distilled water).
• Dose volume for amcenestrant and everolimus for oral administration 10 ml/kg.
• mice were pooled and randomly distributed to the treatment and control groups (10 mice per group), where median tumor volumes for each group was 119 mm 3 .
• Treatments of amcenestrant and everolimus were initiated on day 1 .
• amcenestrant was orally administered at 10 mg/kg BID (8 hours apart), and everolimus was orally administered at 10 mg/kg BIW. Animal body weight was assessed daily.
• the dosages are expressed in mg/kg and based on daily body weight per animal. Vehicle treated animals were used as controls. Mice were checked daily for adverse clinical reactions. Individual mice were weighed daily until the end of the experiment. Mice were euthanized when morbid or weight loss >20% was observed. Tumors were measured with a caliper twice weekly until final sacrifice. When a tumor size reached approximately 3000 mm 3 or when there were animal health issues (40% area of a tumor ulcerated), animals were euthanized, and date of death recorded. Solid tumor volumes were estimated from two-dimensional tumor measurements and calculated according to the following equation: length (mm) x width 2 (mm 2 )
• a dosage producing either 15% body weight loss during 3 consecutive days for an individual mouse, 20% body weight loss during 1 day, or 10% or more drug related deaths were considered an excessively toxic dosage, unless under certain circumstances bodyweight loss or animal death could be considered non-drug related.
• Examples include E2 supplement related body weight loss and urine scalding, animal handling issues such as misgavage, tumor model related issues such as tumor induced cachexia leading to body weight loss that can be observed in control, or vehicle treated groups and excessive tumor ulceration. Mice that had non-drug related death or significant bodyweight loss were not considered toxic and were excluded from statistical analysis. Animal body weight included the tumor weight.
• the primary efficacy end points include tumor volume changes from baseline summarized by the ratio of medians of tumor volume changes from baseline between the treated and control groups (AJ/ C). Changes in tumor volume for each treated (T) and control (C) group were calculated for each animal on each day by subtracting the tumor volume on the day of first treatment (staging day) from the tumor volume on the specified observation day. The median AT was calculated for the treated group and the median DO was calculated for the control group. The ratio DT/DO was calculated and expressed as percentage:
• DT/AC ⁇ 40% is considered as therapeutically active
• DT/DO ⁇ 0% is considered as tumor regression (very active).
• DT/DO > 40% is considered as therapeutically inactive.
• Percent tumor regression is defined as % (percentage) of tumor volume decrease in the treated group on a specified observation day compared to its volume when the study was initiated. At a specific time point (t) and for each animal, the regression percentage was calculated using the following formula:
• the median percent regression for a group on a given day was then calculated by taking the median of individual % regression values calculated for each animal in the group.
• the day of calculation was determined by the day when DT/DO is calculated, except if median percent regression was not representative of the activity of the group. In this case, the day was determined by the first day when the median percent regression was maximal.
• ANOVA analysis of variance
• Tumor volume changes from baseline were calculated for each animal and each day by subtracting the tumor volume on the day of first treatment (day 0) from the tumor volume on the specified observation day.
• Amcenestrant at 10 mg/kg BID, everolimus 10 mg/kg BIW and the combination of amcenestrant and everolimus at the doses and regime for 28 days were tolerated, and no drug-related body weight loss/animal death was observed in the study. But we observed E2 supplement-related significant body weight loss or death, which was excluded from data statistical analysis.
• the combination treatment demonstrated statistically significant anti-tumor efficacy (tumor regression) with DT/DO value of - 31% (p ⁇ 0.0001) on day 28.
• amcenestrant at 10 mg/kg twice a day combined with the mTOR inhibitor everolimus at 10 mg/kg twice a week in MCF7 human breast cancer cell line xenograft model in NOD/SCID mice induced significant anti-tumor efficacy that was superior to single agents alone, and induced tumor growth inhibition and tumor regression.
• Table 1 Efficacy of amcenestrant (SAR439859) combined with everolimus against orthotopic MCF7 human breast cancer xenograft in NOD/SCID mice. PO: per os
• Table 2 Efficacy of amcenestrant (SAR439859) combined with everolimus against orthotopic human breast cancer cell line MCF7 xenograft model in NOD/SCID mice.
• Table 3 Efficacy of amcenestrant (SAR439859) combined with everolimus against orthotopic human breast cancer cell line MCF7 xenograft model in NOD/SCID mice. Comparison of amcenestrant 10 mg/kg and everolimus 10 mg/kg as single agents versus the combination at each day.

Landscapes

• Health & Medical Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Epidemiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• Oncology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (1)

Family

ID=75825773

Family Applications (1)

Country Status (8)

Cited By (7)

Citations (3)

• 2022
  • 2022-04-08 TW TW111113410A patent/TW202304424A/zh unknown
  • 2022-04-11 AR ARP220100914A patent/AR125330A1/es not_active Application Discontinuation
  • 2022-04-12 WO PCT/EP2022/059704 patent/WO2022218958A1/en not_active Ceased
  • 2022-04-12 ES ES22722256T patent/ES3036485T3/es active Active
  • 2022-04-12 EP EP22722256.9A patent/EP4322942B1/en active Active
  • 2022-04-12 CN CN202280027705.5A patent/CN117177743A/zh active Pending
  • 2022-04-12 US US18/286,496 patent/US20240197692A1/en active Pending
  • 2022-04-12 JP JP2023562510A patent/JP2024516795A/ja active Pending

Patent Citations (3)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events